A Glycosylated, Labionin-Containing Lanthipeptide with Marked Antinociceptive Activity
Citations Over TimeTop 11% of 2013 papers
Abstract
Among the growing family of ribosomally synthesized, post-translationally modified peptides, particularly intriguing are class III lanthipeptides containing the triamino acid labionin. In the course of a screening program aimed at finding bacterial cell wall inhibitors, we discovered a new lanthipeptide produced by an Actinoplanes sp. The molecule, designated NAI-112, consists of 22 amino acids and contains an N-terminal labionin and a C-terminal methyl-labionin. Unique among lanthipeptides, it carries a 6-deoxyhexose moiety N-linked to a tryptophan residue. Consistently, the corresponding gene cluster encodes, in addition to the LanKC enzyme characteristic of this lanthipeptide class, a glycosyl transferase. Despite possessing weak antibacterial activity, NAI-112 is effective in experimental models of nociceptive pain, reducing pain symptoms in mice in both the formalin and the chronic constriction injury tests. Thus, NAI-112 represents, after the labyrinthopeptins, the second example of a lanthipeptide effective against nociceptive pain.
Related Papers
- → Synthetic Approaches for the Construction of Five- and Six-Membered Silaazacycles(2022)15 cited
- → Synthesis and Shuttling Behavior of [2]Rotaxanes with a Pyrrole Moiety(2016)26 cited
- → Oxidation of Unsymmetrically Substituted Quaterthiophene with Two Terminal Ferrocenyl Groups(2009)11 cited
- Design, synthesis and evaluation of novel hydroxyethylamine derivatives with nitrogen heterocyclic moiety at N-terminal as BACE1 inhibitors(2010)
- STUDY ON INTRAMOLECULAR SYNERGISTIC INHIBITIVE EFFECTS OF BENZOTRIAZOLY MOIETY AND INIDAZOLY MOIETY(2009)